Abstract Number: L22 • 2019 ACR/ARP Annual Meeting
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…Abstract Number: 1724 • 2019 ACR/ARP Annual Meeting
Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) can be a severe disease, especially when diagnosed in childhood. Onset prior to puberty (Tanner stage II) is rare, and…Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…Abstract Number: 1728 • 2019 ACR/ARP Annual Meeting
Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus
Background/Purpose: Avascular necrosis (AVN) is a serious comorbidity of juvenile systemic lupus erythematosus (jSLE) associated with disability, impaired quality of life, and increased cost of…Abstract Number: 2719 • 2019 ACR/ARP Annual Meeting
Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers
Background/Purpose: The transition from pediatric to adult-oriented health care represents a vulnerable period for young adults with chronic rheumatic diseases. In spite of this, a…Abstract Number: 1746 • 2019 ACR/ARP Annual Meeting
Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers
Background/Purpose: Antiphospholipid antibodies (aPL) have been extensively reported in children; however, research on thrombotic risks associated with aPL among pediatric patients is scarce. Positive aPL…Abstract Number: 2721 • 2019 ACR/ARP Annual Meeting
Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
Background/Purpose: Dyscognition, including loss of mental clarity and problems with attention and memory, often affects adolescents with juvenile fibromyalgia syndrome (JFMS). Our understanding of this…Abstract Number: 1747 • 2019 ACR/ARP Annual Meeting
Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease
Background/Purpose: Renal disease is common in ANCA-associated vasculitis (AAV) and one of the goals of early treatment is to maximize renal function recovery. Corticosteroids are…Abstract Number: 2722 • 2019 ACR/ARP Annual Meeting
The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes
Background/Purpose: Down syndrome arthropathy (DA) is under-recognized with a 19-month average delay in diagnosis (1). The majority present with polyarticular, rheumatoid factor (RF) and anti-nuclear…Abstract Number: 1748 • 2019 ACR/ARP Annual Meeting
Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Background/Purpose: Hydroxychloroquine (HCQ), a medication used to treat Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE) and Sjogren’s Syndrome (SS), reduces disease flare-ups, organ damage,…Abstract Number: 2727 • 2019 ACR/ARP Annual Meeting
Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Background/Purpose: Though mainly found intracellularly, we recently observed mitochondrial extrusion upon cell death, contributing to inflammation and organ damage in lupus-prone mice. Of note, mitochondria…Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…Abstract Number: 2864 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was…Abstract Number: 1753 • 2019 ACR/ARP Annual Meeting
Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?
Background/Purpose: Youths with childhood-onset chronic rheumatic diseases (ChildCRD), including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD), have worse grade 12 standards tests results…Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 52
- Next Page »